|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
WO1989012624A2
(en)
|
1988-06-14 |
1989-12-28 |
Cetus Corporation |
Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
ZA902949B
(en)
|
1989-05-05 |
1992-02-26 |
Res Dev Foundation |
A novel antibody delivery system for biological response modifiers
|
|
US5460785A
(en)
|
1989-08-09 |
1995-10-24 |
Rhomed Incorporated |
Direct labeling of antibodies and other protein with metal ions
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
|
CA2078689C
(en)
|
1990-03-20 |
2003-02-11 |
Sherie L. Morrison |
Chimeric antibodies with receptor binding ligands in place of their constant region
|
|
DK0574395T3
(da)
|
1990-11-09 |
2002-10-07 |
Stephen D Gillies |
Cytokin-immunkonjugater
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5817310A
(en)
|
1991-12-02 |
1998-10-06 |
Cor Therapeutics, Inc. |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
|
|
NZ246242A
(en)
*
|
1991-12-02 |
1996-01-26 |
Cor Therapeutics Inc |
Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf)
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5922545A
(en)
|
1993-10-29 |
1999-07-13 |
Affymax Technologies N.V. |
In vitro peptide and antibody display libraries
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
DE69835143T2
(de)
|
1997-01-21 |
2007-06-06 |
The General Hospital Corp., Boston |
Selektion von proteinen mittels rns-protein fusionen
|
|
US6261804B1
(en)
|
1997-01-21 |
2001-07-17 |
The General Hospital Corporation |
Selection of proteins using RNA-protein fusions
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP0975748B1
(en)
|
1997-04-23 |
2006-03-29 |
Universität Zürich |
Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
|
|
GB2339430A
(en)
|
1997-05-21 |
2000-01-26 |
Biovation Ltd |
Method for the production of non-immunogenic proteins
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
DK1068241T3
(da)
|
1998-04-02 |
2008-02-04 |
Genentech Inc |
Antistofvarianter og fragmenter deraf
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
WO1999051773A1
(en)
|
1998-04-03 |
1999-10-14 |
Phylos, Inc. |
Addressable protein arrays
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6846655B1
(en)
|
1998-06-29 |
2005-01-25 |
Phylos, Inc. |
Methods for generating highly diverse libraries
|
|
ATE437844T1
(de)
|
1998-08-17 |
2009-08-15 |
Bristol Myers Squibb Co |
Identifizierung von verbindung-protein wechselwirkungen mit bibliotheken von gekoppelten protein-nukleinsäure-molekülen
|
|
EP1105516A4
(en)
|
1998-08-17 |
2002-01-09 |
Phylos Inc |
METHODS FOR PRODUCING PRIVATE NUCLEIC ACIDS FROM 3 'NON-TRANSLATED REGIONS AND FOR OPTIMIZING THE FORMATION OF A CELL-PROTEIN RNA FUSION
|
|
AU770555B2
(en)
|
1998-08-17 |
2004-02-26 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
NZ511699A
(en)
|
1998-12-02 |
2003-02-28 |
Phylos Inc |
DNA-protein fusions and uses thereof
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
DE69934967T2
(de)
|
1998-12-08 |
2007-12-06 |
Biovation Ltd. |
Verfahren zur verminderung der immunogenität von proteinen
|
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
IL146015A0
(en)
|
1999-06-01 |
2002-07-25 |
Phylos Inc |
Methods for producing 5'-nucleic acid-protein conjugates
|
|
NZ515292A
(en)
|
1999-07-12 |
2003-08-29 |
Phylos Inc |
Protein with a puromycin tag covalently bonded to the protein's C-terminal
|
|
CA2377468C
(en)
|
1999-07-27 |
2010-04-20 |
Phylos, Inc. |
Peptide acceptor ligation methods
|
|
EP1212452B1
(en)
|
1999-08-27 |
2013-07-17 |
Bristol-Myers Squibb Company |
Methods for encoding and sorting in vitro translated proteins
|
|
US7022479B2
(en)
|
2000-01-24 |
2006-04-04 |
Compound Therapeutics, Inc. |
Sensitive, multiplexed diagnostic assays for protein analysis
|
|
WO2001053539A1
(en)
|
2000-01-24 |
2001-07-26 |
Phylos, Inc. |
Sensitive, multiplexed diagnostic assays for protein analysis
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
|
EP1390741B1
(en)
|
2001-04-17 |
2012-10-31 |
Abmaxis, Inc. |
Structure-based construction of human antibody library
|
|
AU2002310502A1
(en)
|
2001-06-21 |
2003-01-08 |
Phylos, Inc. |
In vitro protein interaction detection systems
|
|
JP2005289809A
(ja)
*
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
US7125669B2
(en)
|
2001-11-27 |
2006-10-24 |
Compound Therapeutics, Inc. |
Solid-phase immobilization of proteins and peptides
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
EP1487879B1
(en)
|
2002-03-01 |
2012-12-26 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
JP4459810B2
(ja)
|
2002-08-14 |
2010-04-28 |
マクロジェニクス，インコーポレーテッド |
ＦｃγＲＩＩＢ特異的抗体とその利用法
|
|
EP3321282A1
(en)
|
2002-09-27 |
2018-05-16 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
JP4768439B2
(ja)
|
2002-10-15 |
2011-09-07 |
アボット バイオセラピューティクス コーポレイション |
変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
|
|
GB0226729D0
(en)
*
|
2002-11-15 |
2002-12-24 |
Medical Res Council |
Intracellular antibodies
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
EP2502935B1
(en)
|
2003-08-22 |
2017-03-29 |
Biogen MA Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
ATE437184T1
(de)
|
2004-01-12 |
2009-08-15 |
Applied Molecular Evolution |
Varianten der fc-region
|
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
DK2471813T3
(en)
|
2004-07-15 |
2015-03-02 |
Xencor Inc |
Optimized Fc variants
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
US8460364B2
(en)
|
2006-07-20 |
2013-06-11 |
Orbusneich Medical, Inc. |
Bioabsorbable polymeric medical device
|
|
US20080206585A1
(en)
*
|
2007-02-22 |
2008-08-28 |
Kennametal Inc. |
Composite materials comprising a hard ceramic phase and a Cu-Ni-Mn infiltration alloy
|
|
MX2009011226A
(es)
*
|
2007-04-17 |
2010-04-01 |
Imclone Llc |
Inhibidores especificos pdgfrbeta.
|
|
US20110022149A1
(en)
|
2007-06-04 |
2011-01-27 |
Cox Brian J |
Methods and devices for treatment of vascular defects
|
|
SI2274008T1
(sl)
*
|
2008-03-27 |
2014-08-29 |
Zymogenetics, Inc. |
Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
|
|
CN102177438A
(zh)
|
2008-07-25 |
2011-09-07 |
理查德·W·瓦格纳 |
蛋白筛选方法
|
|
WO2011056997A1
(en)
*
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
|
ES2926988T3
(es)
*
|
2011-03-15 |
2022-10-31 |
X Body Inc |
Métodos de cribado de anticuerpos
|
|
CN102250249A
(zh)
*
|
2011-06-18 |
2011-11-23 |
常州亚当生物技术有限公司 |
一种抗VEGF/PDGFRbeta双特异性抗体及其应用
|
|
WO2013085972A1
(en)
*
|
2011-12-05 |
2013-06-13 |
X-Body, Inc. |
Pdgf receptor beta binding polypeptides
|